Does SATRALIZUMAB Cause Off label use? 26 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 26 reports of Off label use have been filed in association with SATRALIZUMAB (Enspryng). This represents 11.9% of all adverse event reports for SATRALIZUMAB.
26
Reports of Off label use with SATRALIZUMAB
11.9%
of all SATRALIZUMAB reports
2
Deaths
16
Hospitalizations
How Dangerous Is Off label use From SATRALIZUMAB?
Of the 26 reports, 2 (7.7%) resulted in death, 16 (61.5%) required hospitalization, and 1 (3.8%) were considered life-threatening.
Is Off label use Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SATRALIZUMAB. However, 26 reports have been filed with the FAERS database.
What Other Side Effects Does SATRALIZUMAB Cause?
Neuromyelitis optica spectrum disorder (46)
Urinary tract infection (21)
Muscular weakness (19)
Optic neuritis (15)
Hypoaesthesia (14)
Infection (14)
Pneumonia (13)
Covid-19 (11)
Fatigue (11)
Pain (11)
What Other Drugs Cause Off label use?
RITUXIMAB (39,751)
INFLIXIMAB (34,801)
DENOSUMAB (34,612)
METHOTREXATE (24,020)
VEDOLIZUMAB (21,017)
ETANERCEPT (20,178)
TOCILIZUMAB (18,256)
PREDNISONE (17,867)
LENALIDOMIDE (17,017)
ADALIMUMAB (16,417)
Which SATRALIZUMAB Alternatives Have Lower Off label use Risk?
SATRALIZUMAB vs SATRALIZUMAB-MWGE
SATRALIZUMAB vs SAXAGLIPTIN
SATRALIZUMAB vs SCHOLL'S INGROWN TOENAIL PAIN RELIEVER
SATRALIZUMAB vs SCOPOLAMINE
SATRALIZUMAB vs SCOPOLAMINE HYDROBROMIDE